Navigation Links
OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Date:11/5/2008

BOTHELL, WA and VANCOUVER, Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that the Company's third quarter financial results will be released on Monday, November 10, 2008, and that the Company will host a conference call and live webcast at 4:30 p.m. EDT that afternoon. Management will discuss the company's third quarter results and provide an update on the business and product pipeline.

To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at http://www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-548-7903 (U.S. & Canada) or 719-325-4917 (International). A webcast replay will be available approximately two hours after the call and will be archived on http://www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at http://www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
2. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
3. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
4. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
5. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
6. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
7. OncoGenex increases economic interest in lead cancer drug OGX-011
8. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
9. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
10. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
11. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... LITTLETON, MA. (PRWEB) , ... ... ... Incorporated, the Northeast's premier provider of high quality relocatable and permanent modular ... space combines visual management tools and modern office design characteristics to help ...
(Date:5/23/2017)... ... May 23, 2017 , ... A recent survey conducted ... troublesome and difficult to control weed in 12 categories of broadleaf crops, fruits and ... weed scientists across the U.S. and Canada participated in the 2016 survey, the second ...
(Date:5/23/2017)... ... 2017 , ... Vortex Biosciences , provider of circulating tumor cell (CTC) ... cells using Vortex microfluidic technology ” in Nature Precision Oncology on May 8th. ... Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. The publication ...
(Date:5/23/2017)... Greifensee, Switzerland (PRWEB) , ... May 23, 2017 ... ... which forces machine manufacturers to re-engineer their control technology again and again. METTLER ... common problem for machine manufacturers. The videos illustrate how integration of the ACT350 ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
(Date:3/23/2017)... India , March 23, 2017 The report "Gesture ... Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, ... at a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):